Ambrx Biopharma Inc. - ADR

The momentum for this stock is not very good. Ambrx Biopharma Inc. - ADR is not a good value stock. Ambrx Biopharma Inc. - ADR is not very popular among insiders. Tradey thinks it is not wise to invest in Ambrx Biopharma Inc. - ADR.

News

Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal

Benzinga Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal.\n more…

Are Medical Stocks Lagging DexCom (DXCM) This Year?

Zacks Investment Research For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention...\n more…

Ambrx Biopharma's Landmark Merger and Corporate Overhaul

TipRanks Financial Blog The latest update is out from Ambrx Biopharma (AMAM). The recent merger led to significant changes for a company, including the termination of its Employee Share Pu...\n more…

Ambrx Biopharma shareholders approve acquisition by Johnson & Johnson

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Ambrx Biopharma ticks higher as HSR waiting period for J&J deal expires

Seeking Alpha - Healthcare Ambrx Biopharma ticks higher as HSR waiting period for J&J deal expires...\n more…

Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year...\n more…